Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “CHOLECALCIFEROL”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 505 records · Page 28Linked to original sources
PubMedDate not supplied

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial.

CONTEXT: Alendronate sodium reduces fracture risk in postmenopausal women who have vertebral fractures, but its effects on fracture risk have not been studied for women without vertebral fractures. OBJECTIVE: To test the hypothesis that 4 years of alendronate would decrease the risk of clinical and vertebral fractures in women who have low bone mineral density (BMD) but no vertebral fractures. DESIGN: Randomized, blinded, placebo-controlled trial. SETTING: Eleven community-based clinical research centers. SUBJECTS: Women aged 54 to 81 years with a femoral neck BMD of 0.68 g/cm2 or less (Hologic Inc, Waltham, Mass) but no vertebral fracture; 4432 were randomized to alendronate or placebo and 4272 (96%) completed outcome measurements at the final visit (an average of 4.2 years later). INTERVENTION: All participants reporting calcium intakes of 1000 mg/d or less received a supplement containing 500 mg of calcium and 250 IU of cholecalciferol. Subjects were randomly assigned to either placebo or 5 mg/d of alendronate sodium for 2 years followed by 10 mg/d for the remainder of the trial. MAIN OUTCOME MEASURES: Clinical fractures confirmed by x-ray reports, new vertebral deformities detected by morphometric measurements on radiographs, and BMD measured by dual x-ray absorptiometry. RESULTS: Alendronate increased BMD at all sites studied (P<.001) and reduced clinical fractures from 312 in the placebo group to 272 in the intervention group, but not significantly so (14% reduction; relative hazard [RH], 0.86; 95% confidence interval [CI], 0.73-1.01). Alendronate reduced clinical fractures by 36% in women with baseline osteoporosis at the femoral neck (>2.5 SDs below the normal young adult mean; RH, 0.64; 95% CI, 0.50-0.82; treatment-control difference, 6.5%; number needed to treat [NNT], 15), but there was no significant reduction among those with higher BMD (RH, 1.08; 95% CI, 0.87-1.35). Alendronate decreased the risk of radiographic vertebral fractures by 44% overall (relative risk, 0.56; 95% CI, 0.39-0.80; treatment-control difference, 1.7%; NNT, 60). Alendronate did not increase the risk of gastrointestinal or other adverse effects. CONCLUSIONS: In women with low BMD but without vertebral fractures, 4 years of alendronate safely increased BMD and decreased the risk of first vertebral deformity. Alendronate significantly reduced the risk of clinical fractures among women with osteoporosis but not among women with higher BMD.

Absorptiometry, Photon↗
PubMed1996

Vitamin D analog 25-(OH)-16,23E-Diene-26,27-hexafluoro-vitamin D3 induces differentiation of HL60 cells with minimal effects on cellular calcium homeostasis.

Numerous vitamin D3 analogs (VDAs) can inhibit the proliferation of cells from several types of human malignancies. The physiologically active form of vitamin D3, 1,25-dihydroxyvitamin D3(1,25D3), is formed by successive hydroxylations of cholecalciferol at the 25 and 1 alpha positions. In this study we examined the effects of the absence of the 1 alpha (OH) group, introduction of a double bond in position 16, and further modifications at the 23, 26, and 27 positions in the side chain on the potency of the VDAs. The parameters studied were the rapidity of the induction of monocytic differentiation, the cell cycle traverse, and the effects of VDAs on intracellular calcium homeostasis in HL60 cells. The results show that (1) 1,25D3 derivatives which lace the 1 alpha (OH) group have little differentiation-inducing activity, (2) hexafluorination (6F) of the terminal methyl groups in the side chain partially restores the activity of 1 alpha-desoxy compounds and potentiates the activity of 1 alpha hydroxylated compounds, and (3) 25-(OH)-16,23E-diene-26,27-hexafluoro-vitamin D2 (Ro25-9887) alone among the twelve compounds tested induces differentiation with only minimal changes in the basal levels of intracellular calcium and store-dependent calcium influx in HL60 cells. Addition of 1 alpha (OH) group to this compound increases its differentiation-inducing activity but also elevates basal calcium level. The results suggest that altered calcium homeostasis is not an obligatory component of HL60 leukemia cell differentiation, and that Ro25-9887 and related VDAs may be suitable for testing as components of anti-leukemic therapy.

CD11 Antigens↗
PubMed1987

Electron microscopic cytochemical localization of a basolateral calcium adenosine triphosphatase in vitamin D replete chick enterocytes.

A cytochemical technique for the electron microscopic localization of calcium adenosine triphosphatase (Ca-ATPase) was utilized to localize this enzyme in the enterocytes of rachitic and vitamin D-replete chicks. In animals treated with cholecalciferol (CC, vitamin D3), an electron-dense reaction product was located along the basolateral membranes of the absorptive cells within 72 hr after injection. Similarly, a reaction product was identified in association with the basolateral membranes within 24 hr after injection of 1,25-dihydroxycholecalciferol, the active metabolite of vitamin D. A microvillar reaction product was not seen in either of these two groups. Electron-dense reaction products were also seen in association with mitochondria and scattered throughout the cytoplasm of these enterocytes. The Ca-ATPase reaction product was dependent upon the presence of medium calcium and substrate (ATP), was inhibited by vanadate, and was heat labile. In the rachitic animals, a reaction product indicative of Ca-ATPase activity was not seen in association with either the basolateral membranes or the mitochondria. These data appear to indicate that an energy-requiring calcium-activated membrane pump plays a role in the flux of calcium across the enterocytes of the small intestine.

Animals↗
PubMedDate not supplied

Impact of neonatal imprinting with vitamin A or D on the hormone content of rat immune cells.

Neonatal single vitamin A (retinol; 3 mg) or vitamin D3 (cholecalciferol; 0.05 mg) treatment (imprinting) was done in male and female rats and 2 months later the endorphin, triiodothyronine (T3) and ACTH content of immune cells (peritoneal lymphocytes, monocyte-granulocyte-macrophage group [mo-gran], mast cells and thymic lymphocytes) were studied immunocytochemically by using flow cytometry and confocal microscopy. The T3 content was significantly decreased in peritoneal lymphocytes and in mo-gran and the endorphin content decreased in thymocytes of male animals, while ACTH was decreased in female lymphocytes and mo-gran. Vitamin D treatment was absolutely ineffective. The imprinting effects of vitamins A and D and their differences are discussed. The results call attention to the possible harmful effect of vitamin treatments during the perinatal critical period.

Adrenocorticotropic Hormone↗
PubMed1975

Effect of oral contraceptives on plasma clearance.

The effects of chronic steroid contraceptive therapy on drug clearance from plasma were studied by using plasma antipyrine, phenylbutazone, and cholecalciferol half-lives in women. After 3 mo of oral steroid therapy (Norinyl, 2 mg; norethindrone + mestranol), the antipyrine half-life was increased in 3 of 6 subjects, phenylbutazone half-life was not consistently altered, and vitamin D3 half-life was increased in 3 of 4 patients. After 1 to 7 yr of oral steroid theraphy, the antipyrine half-life was longer while taking the contraceptive than when the contraceptive treatment was discontinued in 4 of 6 subjects, whereas that of phenylbutazone was not consistently altered.

Adolescent↗
PubMed1988

Determination of fat-soluble vitamins in a pharmaceutical dosage form by solid-phase extraction and reversed-phase liquid chromatography.

A rapid and precise method for the determination of fat-soluble vitamins from a water-based multivitamin mixture was developed utilizing solid-phase extraction and reversed-phase high-performance liquid chromatography (HPLC). Cholecalciferol, alpha-tocopherol acetate, and retinol palmitate were extracted in a single stage from the matrix using Bond Elut C18 columns. The vitamins were then chromatographed on a Hypersil 5-microns C18 column, using a water:methanol gradient, and quantified simultaneously using individual UV absorption maxima. The recovery of added analytes varied from 92.6 to 100.6%. The assay coefficient of variation was 1.7-2.7%. The sample preparation method and HPLC assay described here are practical for pharmaceutical quality control purposes.

Cholecalciferol↗
PubMed1996

Purification and characterization of plasma vitamin D binding protein from the snapping turtle, Chelydra serpentina.

Vitamin D binding protein (DBP) was isolated from the plasma of the snapping turtle, Chelydra serpentina (mixed sex adult), and compared with the previously characterized dual function binding plasma protein that binds both thyroxine (T4) and vitamin D (tsTDBP) in an emydid turtle, Trachemys scripta. Purification of Chelydra serpentina DBP (csDBP) was accomplished by ion exchange chromatography, preparative polyacrylamide gel electrophoresis, and reverse-phase high-performance liquid chromatography. Estimates of increased purification (ca. 71-fold), recovery (ca. 1.5%), and corresponding plasma concentration (ca. 0.6 mg/ml) are confounded by interference with other proteins. A protein was identified that showed the same high affinity for 25-OH-cholecalciferol (vitamin D3) as the tsTDBP, and the two exhibited similar heat resistances in binding. The csDBP and tsTDBP had similar molecular weights by SDS-PAGE (ca. 58 kDa), showed immunological cross reactivity, and differed by only three residues, representing conservative substitutions, in the 30 NH2-terminal amino acid sequence. A slightly lesser homology (up to 89% similarity based on conservative substitutions) was seen with three mammalian DBPs. However, unlike tsTDBP, the DBP from the snapper did not bind T4. These data support the view that the DBP of emydid turtles secondarily evolved a second T4 binding site, and this is probably independent of the D3 binding domain.

Amino Acid Sequence↗
PubMed1990

Cerebrocortical oxygen supply of sclerotic rats and acute diltiazem therapy.

The therapeutic effects of calcium antagonist diltiazem on cerebrovascular smooth muscle of sclerotic and normal rats has been investigated. Arteriosclerosis was caused by treatment of the rats with a water soluble 1,25-dihydro-cholecalciferol in a dose of 97,000 IU. After 2-4 days, serum urea of the treated animals was increased from 56 +/- 8 to 78 +/- 17 mg/dl. Histological examinations of tissue probes from kidneys, heart, aorta and the major arteries by means of the staining method according to von Kossa clearly showed the picture of the Mönckeberg-type atherosclerosis. The calcified rats (N = 23) and the control group (N = 25) were anesthetized with ketamine/xylazine. Following craniotomy and tracheotomy for artificial ventilation, surface PO2 of the cerebro-cortex and cerebral blood flow via the inhalatory hydrogen clearance technique were measured. Surface PO2 frequency distribution of vitamin D3 treated animals showed a left shift (mean +/- SD = 29 +/- 8 compared with 34 +/- 6 mm Hg for controls) and a CBF decrease (1.36 +/- 0.51 compared to 1.50 +/- 0.60 ml/g.min for the controls). Diltiazem infusion of 2 ml/h corresponding to 5 micrograms/kg bw after 5 minutes caused a slight CBF decrease (1.50 +/- 0.60 to 1.43 +/- 0.78 ml/g.min) in controls and an insignificant CBF reduction in sclerotic rats. Mean arterial blood pressure was lowered by diltiazem infusion. The hypertensive sclerotic rats became almost normal (148 +/- 18 to 91 +/- 15 mm Hg) while the control animals decreased in MAP from 118 to 80 +/- 15 mm Hg.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗
PubMed1989

Effects of vitamin D derivatives on soft tissue calcification in neonatal and calcium mobilization in adult rats.

The activity of 18 vitamin D analogs on soft tissue calcification and growth impairment in neonatal rats and their effect on bone calcium mobilization, intestinal calcium absorption and binding to intestinal 1,25-dihydroxyvitamin D3 receptors in adult rats were compared. Depending on the chemical modification of the vitamin D parent compounds, they could be separated into active and inactive analogs. Cholecalciferol and ergocalciferol were similarly active, but epimerization of ergocalciferol at carbon 23 caused loss of activity. Hexafluorination at carbon 26 and 27 and the introduction of a double bond at carbon 22 or 23 had no or little effect on the activity. The loss of activity was caused by the introduction of a triple bond at carbon 23 and by hydroxylation at carbon 23, 26 or 28. The differentiation of human promyelocytic leukemia cells (HL-60) induced by these derivatives was used as a parameter for antitumour activity. All six analogs, which markedly affected calcium metabolism, were highly active in HL-60 cells. However, at least three derivatives were highly active in the antitumour test but failed to induce hypercalcemia. Thus, these results indicate that it could be possible to develop medically useful vitamin D derivatives devoid of hypercalcemic side-effects.

Animals↗
PubMed1983

In vitro effects of vitamin D3 on the phospholipids of isolated renal brush border membranes.

A model system is described in which cholecalciferol (vitamin D3) is incorporated into phosphatidylcholine liposomes and then the liposomes are incubated in vitro with isolated renal brush border membrane vesicles. The incubation results in an alteration of the phospholipid composition, the fluidity, and the transport properties of the membrane. The findings provide evidence consistent with the hypothesis that vitamin D3 and metabolites modify membrane structure and function by "liponomic regulation."

Animals↗
PubMed2005

Limited availability of nutritional vitamin D causing inappropriate treatment of vitamin D deficiency rickets with a response resembling pseudohypoparathyroidism type II in a Japanese patient.

Vitamin D deficiency rickets occasionally resembles pseudohypoparathyroidism type II (PHP type II) with respect to the response to exogenous PTH in the presence of hypocalcemia. We encountered a Japanese patient with stage 2 vitamin D deficiency rickets, who had increased urinary cAMP excretion and no response of urinary phosphate or N-acetyl-beta-D-glucosaminidase excretion to exogenous PTH under normocalcemic and normophosphatemic conditions, after treatment with 1,25(OH)2 vitamin D3. This case shows that it is possible for a response mimicking that of PHP type II to occur when the serum calcidiol level is low due to causes other than hypocalcemia and secondary hyperparathyroidism. When the serum calcidiol level is low, the appropriate treatment should be cholecalciferol or ergocalciferol. However, because neither is commercially available as a useful formulation in Japan, physicians are forced to inappropriately use calcitriol or analogs.

Calcifediol↗
PubMed2005

Exercise maintains bone density at spine and hip EFOPS: a 3-year longitudinal study in early postmenopausal women.

It is an important aim in the prevention of osteoporosis to stop or decelerate bone loss during the early postmenopausal years. Here we report on results of the 3-year EFOPS exercise trial in osteopenic women. The exercise strategy emphasized low-volume high-resistance strength training and high-impact aerobics. Forty-eight fully compliant women (55.1+/-3.3 years) with no medication or illness affecting bone metabolism participated in the exercise group (EG); 30 women (55.5+/-3.0 years) served as non-training controls (CG). At baseline there were no significant between-group differences with respect to physical fitness, bone mineral density, pain and nutritional status. The training consisted of two group training and two home training sessions per week. The study participants of both groups were individually supplemented with calcium and vitamin D (cholecalciferol). Bone mineral density (BMD) was measured by DXA at the lumbar spine, proximal femur and distal forearm and by QCT at the lumbar spine. Speed of sound and broadband ultrasound attenuation were determined at the calcaneus by quantitative ultrasound (QUS). Pain frequency and intensity at different skeletal sites were assessed via questionnaire. After 38 months, the following within-group changes were measured: DXA lumbar spine, EG: 0.8% n.s.; CG: -3.3% P<0.001; QCT trabecular ROI, EG: 1.1% n.s; CG: -7.7% P<0.001; QCT cortical ROI, EG: 5.3% P<0.001; CG: -2.6% P<0.001; DXA total hip: EG: -0.2% n.s; CG -1.9%, P<0.001; DXA distal forearm, EG: -2.8% P<0.001; CG: -3.8% P<0.001; BUA, EG: -0.3% n.s; CG -5.4% P<0.001; SOS, EG: 0.3% n.s; CG -1.0% P<0.001. At year 3 between-group differences relative to the exercise group were: DXA lumbar spine: 4.1% P<0.001; QCT trabecular ROI: 8.8% P<0.001; QCT cortical ROI: 7.9% P<0.001; DXA total hip: 2.1%, P<0.001; DXA distal forearm: 1.0% n.s.; BUA: 5.8% P<0.05; SOS: 1.3% P<0.001. Pain frequency and intensity in the spine significantly decreased in the exercise group and increased in the control group, while no between-group differences were detected in the main joints. In summary, over a period of 3 years our low-volume/high-intensity exercise program was successful to maintain bone mineral density at the spine, hip and calcaneus, but not at the forearm.

Aging↗
PubMed1998

Does vitamin D strengthen the increase in femoral neck BMD in osteoporotic women treated with estrogen?

The long-term effects on bone of estrogen therapy (HRT) combined with vitamin D3 supplementation were evaluated and compared with the effects of HRT without vitamin D3 supplementation in a 4-year prospective, partly randomized study among 60 osteoporotic women (mean age 55.4 years; range 49.7-59.4 years). The women studied were a subgroup of the population-based Kuopio Osteoporosis Risk Factor and Prevention Study (OSTPRE) (n = 13,100). The bone mineral densities (BMD) of the lumbar spine and femoral neck were determined by dual-energy X-ray absorptiometry (DXA) in 3236 perimenopausal women. Those 106 women with baseline BMD more than 2 SDs less than the mean value in this population, either at the lumbar spine (BMD < 0.826 g/cm2) and/or femoral neck (BMD < 0.684 g/cm2), were offered treatment for osteoporosis. After exclusions, 60 women were included in the analyses. Group allocation was: HRT (estradiol valerate (2 mg) plus cyproterone acetage, 1 mg, sequentially: ClimenR) (n = 21); HRT + Vit D: Climen + vitamin D3 (cholecalciferol, 300 IU/day, no intake during June-August) (n = 23); controls: 16 women who refused all treatment served as a non-randomized control group. In the HRT group, the highly significant increase in lumbar BMD was 5.4%, 5.3%, 4.7% and 4.0% after 1, 2, 3 and 4 years of treatment, respectively, all compared with the baseline values and with the control group. The increase in femoral neck BMD was statistically insignificant (1.4%, 2.2%, 1.9% and 2.1%, respectively; p > 0.05). In the HRT + Vit D group, the lumbar BMD increased by 3.7%, 4.9%, 4.9% and 4.9% (p < 0.001), whereas the 5.8% increase in femoral neck BMD reached significance at 4 years (p < 0.01) when compared with the control group as well as with the baseline values. However, there were no statistically significant differences in lumbar or femoral BMD changes between the two HRT groups. In conclusion, estrogen can substantially increase lumbar bone mass in patients with postmenopausal osteoporosis. In addition, the combination of HRT and vitamin D3 may increase femoral neck BMD in osteoporotic women more than estrogen alone.

Androgen Antagonists↗
PubMed2003

Automated method for the determination of vitamin D3 hydroxymetabolites in serum.

An almost automated method for the determination of hydroxymetabolites of vitamin D(3) (cholecalciferol) in human serum is reported. The method consists of three steps: 1) a batch liquid-liquid extraction step with 2-propanol and hexane, and drying of the extract and reconstitution with phosphate buffer. 2) A cleanup and preconcentration step based on solid-phase extraction using Prospekt equipment, with CN group cartridges and elution with the chromatographic mobile phase. 3) A chromatographic step for individual separation of the target analytes starting with a 90:10 methanol-water mixture, then a linear gradient to obtain 100% methanol; followed by photometric detection. The method provides a linear range between 1.0 and 100 ng mL(-1) for 24,25-(OH)(2) vitamin D(3) and for 25-(OH)(2) vitamin D(3), and between 1.5 and 100 ng mL(-1) for 1,25-(OH) vitamin D(3), with correlation coefficients ranging between 0.993 and 0.987, repeatability between 1.9% and 4.8% and within-laboratory reproducibility between 2.8% and 8.8%.

Automation↗
PubMed1985

The analyses of six common vitamins by laser desorption mass spectroscopy.

The ability to obtain molecular fragmentation patterns at localized (microprobe level) sites would be of great aid to analytical biochemists in mapping the sites, and thus deducing the many functions of bioorganic species, such as vitamins. Laser desorption mass spectroscopy has this ability to provide molecular fragmentation patterns at the microprobe level. In this preliminary study, six common vitamins--ascorbic acid, retinoic acid, pyridoxine monohydrochloride, riboflavin, thiamine hydrochloride, and cholecalciferol--are analyzed as pure compounds by laser desorption mass spectroscopy. Spectra and commentary about the fragmentation patterns for all six vitamins are included.

Ascorbic Acid↗
PubMed1988

24-Dehydrovitamin D is potent inhibitor of rat liver microsomal vitamin D-25-hydroxylase.

A pathway has been described in the skin for the synthesis of 24-dehydrovitamin D3 (delta 24D3) from 24-dehydroprovitamin D3. The physiologic function of delta 24D3 is unknown, but has been proposed as a potential inhibitor of hepatic vitamin D-25-hydroxylase. We validated an assay for vitamin D-25-hydroxylase in rat hepatic microsomes, using nanomolar amounts of [3H]D3 as substrate, and found that delta 24D3 competitively inhibits vitamin D-25-hydroxylase activity. The apparent Ki was approximately 17 nM, indistinguishable from the Km of approximately 15 nM, suggesting that both delta 24D3 and cholecalciferol have similar affinity for the enzyme. We found no [3H]delta 24D3 in serum or liver extracts after repletion of vitamin D-depleted rats with [3H]vitamin D3 for 4 h or 6 days. A dose of 1 microgram delta 24D3 to vitamin D- and calcium-depleted rats was unable to promote any elevation in the 45Ca transport by everted duodenal sacs or to increase levels of plasma calcium: thus no evidence for biological conversion of delta 24D3 to vitamin D3 was observed. Further studies are needed to determine whether delta 24D3 is released from the skin to the circulation and is taken up by the liver, before physiological relevance can be attributed to this inhibitor.

Animals↗
PubMed1979

The effect of DDT on vitamin D metabolism and calcium binding activity in the chick.

The mechanism of DDT impaired calcium absorption was studied in control, DDT fed and starved chicks. The metabolism of [3H]cholecalciferol was the same in the 3 groups, but the DDT fed and starved chicks had less intestinal calcium binding activity than the control chicks. These results suggest that DDT impaired calcium absorption and intestinal calcium binding activity may be a result of DDT induced anorexia.

Animals↗
PubMed1994

Vitamin D influences gap junctional communication in C3H/10T 1/2 murine fibroblast cells.

Vitamin D3, cholecalciferol, induces cell-cell communication via gap junctions in murine fibroblasts (C3H/10T 1/2 cells) at concentrations between 0.01 and 1.0 microM, as assayed by the dye transfer method using Lucifer yellow CH. The extent of induction is similar to that obtained with the positive controls, canthaxanthin or retinoic acid, applied at 10 and 1 microM, respectively. Vitamin D2 also induces cell-cell communication. At elevated concentrations of vitamin D3 (5 microM) there is a suppression of gap junctional communication, reversible upon exposure to all-trans retinoic acid (1 microM) after removal of vitamin D3 from the medium. Conversely, communication between cells prestimulated with retinoic acid (1 microM) rapidly decreases when the retinoid is replaced by vitamin D3 (5 microM). The data demonstrate a role for vitamin D in the regulation of intercellular communication. This novel property of vitamin D may contribute to the antiproliferative effects of vitamin D exhibited in some types of cancer.

Animals↗